Medicare has launched a temporary program to cover obesity drugs for seniors, marking the first time these medications are available through insurance for weight loss alone. The Medicare GLP-1 Bridge program, effective July 1, offers eligible beneficiaries access to GLP-1 medications like Wegovy and Zepbound for $50 a month. This initiative aims to address the high cost of these drugs, which previously ranged from $1,086 to $1,650 monthly.
Immediate Action & Core Facts
Medicare’s new program covers GLP-1 drugs for seniors with a BMI of 35 or higher, or a BMI of 27 with related health conditions. Walmart and CVS Health are assisting patients by providing educational resources and pharmacy support. A survey by the Obesity Care Advocacy Network found that 82% of seniors were unaware of the new coverage.
Deeper Dive & Context
Eligibility and Access
The program excludes seniors already covered for diabetes or other conditions under traditional Medicare. It runs until the end of 2027. Walmart and CVS are offering tools like Everyday Health Signals to help seniors manage their health and navigate the new coverage.
Patient Impact
Barbara Senich, a 69-year-old who has struggled with obesity, highlights the financial burden of GLP-1 drugs. She currently pays for Zepbound through LillyDirect but hopes the new Medicare program will ease costs. The medications have helped her maintain weight loss, but affordability remains a challenge.
Industry and Policy Implications
The program’s temporary nature raises questions about long-term access. Advocates emphasize the need for broader awareness, while critics note the strict eligibility criteria. The coverage could influence future Medicare policies on obesity treatments.